Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines.

ABSTRACT:

Background

Novel messenger RNA (mRNA)-based vaccines play an important role in current vaccination campaigns against SARS-CoV-2. They are highly efficacious and generally well tolerated. Vaccination in patients with immune-mediated kidney diseases is recommended. A number of cases with de novo or relapsing glomerulonephritis shortly after vaccine application have been reported, some of which presented with gross haematuria.

Methods

We collected 10 cases of macrohaematuria following mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at our tertiary care institution and referring centres. Additionally, we pooled all 25 published cases from the literature with ours to analyse their clinical characteristics.

Results

Most macrohaemat

SUBMITTER: Ritter A 

PROVIDER: S-EPMC9050541 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature